215 related articles for article (PubMed ID: 7511289)
1. [Proliferative activity and p53 expression in transitional cell carcinoma of the urinary bladder].
Offner FA; Schäfer G; Hittmair A; Ofner D; Grünewald K; Weyrer K; Mattern D; Eberle J; Mikuz G; Feichtinger H
Verh Dtsch Ges Pathol; 1993; 77():241-6. PubMed ID: 7511289
[TBL] [Abstract][Full Text] [Related]
2. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma.
Zhang ZT; Pak J; Shapiro E; Sun TT; Wu XR
Cancer Res; 1999 Jul; 59(14):3512-7. PubMed ID: 10416618
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder.
Popov Z; Hoznek A; Colombel M; Bastuji-Garin S; Lefrere-Belda MA; Bellot J; Abboh CC; Mazerolles C; Chopin DK
Cancer; 1997 Oct; 80(8):1472-81. PubMed ID: 9338472
[TBL] [Abstract][Full Text] [Related]
4. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
5. Cyclin D1 overexpression in rat two-stage bladder carcinogenesis and its relationship with oncogenes, tumor suppressor genes, and cell proliferation.
Lee CC; Yamamoto S; Wanibuchi H; Wada S; Sugimura K; Kishimoto T; Fukushima S
Cancer Res; 1997 Nov; 57(21):4765-76. PubMed ID: 9354438
[TBL] [Abstract][Full Text] [Related]
6. [Monoclonal antibodies (MIB 1, PC 10, 486p and p53) as prognostic factors for recurrent urothelial carcinoma of the urinary bladder].
Hake R; Vorreuther R; Borchmann P; Lukowsky S; Thiele J; Fischer R
Verh Dtsch Ges Pathol; 1993; 77():236-40. PubMed ID: 7511288
[TBL] [Abstract][Full Text] [Related]
7. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
[TBL] [Abstract][Full Text] [Related]
8. [Ki-67 fraction, p53 alteration and numerical chromosome aberrations (chromosomes 7 and 17) in formalin fixed bladder tumors].
Moch H; Sauter G; Gudat F; Waldman F; Mihatsch MJ
Verh Dtsch Ges Pathol; 1993; 77():226-30. PubMed ID: 7511286
[TBL] [Abstract][Full Text] [Related]
9. CIS is a surrogate marker of genetic instability and field carcinogenesis in the urothelial mucosa.
Palmeira C; Lameiras C; Amaro T; Lima L; Koch A; Lopes C; Oliveira PA; Santos L
Urol Oncol; 2011; 29(2):205-11. PubMed ID: 19854077
[TBL] [Abstract][Full Text] [Related]
10. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification.
Dyrskjøt L; Kruhøffer M; Thykjaer T; Marcussen N; Jensen JL; Møller K; Ørntoft TF
Cancer Res; 2004 Jun; 64(11):4040-8. PubMed ID: 15173019
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
Dekairelle AF; Tombal B; Cosyns JP; Gala JL
Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
[TBL] [Abstract][Full Text] [Related]
12. Cell proliferation of transitional cell bladder cancer determined by PCNA/cyclin immunostaining. A histopathological description.
Lipponen PK; Eskelinen MJ
Anticancer Res; 1992; 12(2):577-83. PubMed ID: 1349799
[TBL] [Abstract][Full Text] [Related]
13. [Expression of PCNA/cyclin, p53, C-erbB-2 versus histological grade in transitional cell carcinoma of urinary bladder].
Yoshikawa H; Ikeuchi T; Iguchi H; Onodera Y; Kai Y
Hinyokika Kiyo; 1995 Apr; 41(4):253-8. PubMed ID: 7785554
[TBL] [Abstract][Full Text] [Related]
14. P53 overexpression in bladder urothelial neoplasms: new aspect of World Health Organization/International Society of Urological Pathology classification.
Kalantari MR; Ahmadnia H
Urol J; 2007; 4(4):230-3. PubMed ID: 18270948
[TBL] [Abstract][Full Text] [Related]
15. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements.
Kunze E; Von Bonin F; Werner C; Wendt M; Schlott T
Int J Mol Med; 2006 Jan; 17(1):3-13. PubMed ID: 16328005
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma.
Zigeuner R; Tsybrovskyy O; Ratschek M; Rehak P; Lipsky K; Langner C
Urology; 2004 Jun; 63(6):1079-83. PubMed ID: 15183954
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.
Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J
Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of p53 and proliferating cell nuclear antigen (PCNA) in bladder cancer: positive immunostaining and radiosensitivity.
Ogura K; Habuchi T; Yamada H; Ogawa O; Yoshida O
Int J Urol; 1995 Nov; 2(5):302-8. PubMed ID: 8749948
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic study of cell proliferative markers ki67, PCNA and p53 oncoprotein in bladder tumors].
Ben Rejeb A; Mahjoub A; Berraies N; Tissaoui K
Ann Urol (Paris); 2000 Aug; 34(4):240-8. PubMed ID: 10994143
[TBL] [Abstract][Full Text] [Related]
20. Expression of p27(Kip1) protein in transitional cell carcinoma of the upper urinary tract.
Nakanishi K; Kawai T; Aida S; Kasamatsu H; Aurues T; Ikeda T
Mod Pathol; 2001 May; 14(5):371-6. PubMed ID: 11353044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
